Biggest News Aggregation in the World
📰 Beigene News

Page 17 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

Brokerages Expect BeiGene, Ltd. (NASDAQ:BGNE) Will Post Quarterly Sales of $332.26 Million

Equities research analysts expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to report sales of $332.26 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for BeiGene’s earnings, with the highest sales estimate coming in at $347.62 million and the lowest estimate coming in at $316.90 million. BeiGene reported […]
United States Xiaobin Wu Assetmark Inc Shaughnessy Asset Management Morgan Stanley Sawtooth Solutions

BeiGene (NASDAQ:BGNE) Downgraded by Zacks Investment Research

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
Cayman Islands United States Xiaobin Wu Morgan Stanley Beigene Company Profile Get Rating Zacks Investment Research

BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for
United States Kevin Mannix Xiaobin Wu Kyle Blankenship Exchange Commission China National Medical Products Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BeiGene (NASDAQ:BGNE) Upgraded to "Buy" at Zacks Investment Research

BeiGene (NASDAQ:BGNE – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $179.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.49% […]
Cayman Islands United States Thomson Reuter Shaughnessy Asset Management Morgan Stanley Assetmark Inc

Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma Seite 1

27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1
United States Mark Lanasa European Medicines Agency Drug Administration Data Monitoring Committee Independent Data Monitoring Committee

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science